Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 19.25
(-3.12%)
CNY 19.25
(-3.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 213.41 Million CNY | 40.43% |
| 2022 | 167.67 Million CNY | 17.25% |
| 2021 | 148.17 Million CNY | -25.06% |
| 2020 | 189.46 Million CNY | -2.36% |
| 2019 | 198.5 Million CNY | 21.95% |
| 2018 | 163.23 Million CNY | 107.03% |
| 2017 | 78.89 Million CNY | -7.69% |
| 2016 | 82.86 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 43.16 Million CNY | 51.56% |
| 2024 Q2 | 46.77 Million CNY | 50.36% |
| 2024 Q3 | 10.06 Million CNY | -87.68% |
| 2023 FY | - CNY | 40.43% |
| 2023 Q1 | 69.43 Million CNY | 211.12% |
| 2023 Q2 | 32.37 Million CNY | -53.38% |
| 2023 Q3 | 26.06 Million CNY | -19.5% |
| 2023 Q4 | 57.69 Million CNY | 121.37% |
| 2022 Q4 | 22.31 Million CNY | 39.12% |
| 2022 Q1 | 48.81 Million CNY | 5642.03% |
| 2022 Q3 | 16.04 Million CNY | -55.28% |
| 2022 Q2 | 35.87 Million CNY | -26.5% |
| 2022 FY | - CNY | 17.25% |
| 2021 Q3 | 38.02 Million CNY | 38.24% |
| 2021 Q1 | 33.91 Million CNY | -18.43% |
| 2021 FY | - CNY | -25.06% |
| 2021 Q4 | 850.05 Thousand CNY | -97.76% |
| 2021 Q2 | 27.5 Million CNY | -18.89% |
| 2020 Q3 | 43.22 Million CNY | 0.88% |
| 2020 Q4 | 41.57 Million CNY | -3.81% |
| 2020 FY | - CNY | -2.36% |
| 2020 Q1 | 26.95 Million CNY | -68.88% |
| 2020 Q2 | 42.84 Million CNY | 58.98% |
| 2019 Q1 | 27.05 Million CNY | 0.0% |
| 2019 FY | - CNY | 21.95% |
| 2019 Q2 | 33.64 Million CNY | 24.35% |
| 2019 Q4 | 86.61 Million CNY | 515.09% |
| 2019 Q3 | 14.08 Million CNY | -58.15% |
| 2018 FY | - CNY | 107.03% |
| 2017 FY | - CNY | -7.69% |
| 2016 FY | - CNY | 0.0% |